Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KALA BIO, Inc.KALA · Entity 7964 | Director | June 12, 2018 | June 14, 2018 |
| Neuronetics, Inc.STIM · Entity 6248 | Director | July 02, 2018 | July 05, 2018 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KALA BIO, Inc.
Report date June 12, 2018 · Filed June 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.73 · Expires 2028-06-11 | Direct | 12,960 |
Reported balance
After 2018-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 12,960 · Balance 12,960 F1: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Neuronetics, Inc.
Report date July 02, 2018 · Filed July 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2028-04-24 | Direct | 8,767 |
Reported balance
After 2018-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-02 · Grant · Acquired 8,767 · Balance 8,767 F1: The performance criterion for vesting of this option was met upon the closing of the Issuer's initial public offering. One twelfth (1/12th) of the shares subject to the option vested or shall vest monthly commencing on March 16, 2018, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The performance criterion for vesting of this option was met upon the closing of the Issuer's initial public offering. One twelfth (1/12th) of the shares subject to the option vested or shall vest monthly commencing on March 16, 2018, subject to Reporting Person continuing to provide service through each such date.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 08, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2018 Filed Jul 5, 2018 20:34 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantStock Option (Right to Buy) · Derivative | 8,767 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-18-041649 · doc4.xml · derivative · entry 1 Hill Paulina · CIK 0001710965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,767 Underlying: Common Stock · 8,767 shares Expires 2028-04-24 F1 · derivative.exercise_date: The performance criterion for vesting of this option was met upon the closing of the Issuer's initial public offering. One twelfth (1/12th) of the shares subject to the option vested or shall vest monthly commencing on March 16, 2018, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:47 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 12,960 | $0.00 Strike: $13.73 | $0.00 |
DisclosureSEC source: 0001179110-18-008525 · edgar.xml · derivative · entry 1 Hill Paulina · CIK 0001710965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,960 Underlying: Common Stock · 12,960 shares Expires 2028-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 20:20 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 12,960 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010595 · edgar.xml · derivative · entry 1 Hill Paulina · CIK 0001710965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,960 Underlying: Common Stock · 12,960 shares Expires 2027-07-18 F1 · derivative.exercise_date: This option was granted, effective on July 19, 2017 and vests over one year, with 8.33% of the shares underlying the option vesting on August 19, 2017, and an addition 8.33% of the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.